These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 18723549)

  • 1. Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib.
    Loriot Y; Boudou-Rouquette P; Billemont B; Ropert S; Goldwasser F
    Ann Oncol; 2008 Nov; 19(11):1975. PubMed ID: 18723549
    [No Abstract]   [Full Text] [Related]  

  • 2. Kidney cancer: Does hypothyroidism predict clinical outcome?
    Rini B
    Nat Rev Urol; 2011 Jan; 8(1):10-1. PubMed ID: 21116300
    [No Abstract]   [Full Text] [Related]  

  • 3. Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib.
    Overkleeft EN; Goldschmeding R; van Reekum F; Voest EE; Verheul HM
    Ann Oncol; 2010 Jan; 21(1):184-5. PubMed ID: 19889617
    [No Abstract]   [Full Text] [Related]  

  • 4. Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma.
    Mego M; Reckova M; Obertova J; Sycova-Mila Z; Brozmanova K; Mardiak J
    Ann Oncol; 2007 Nov; 18(11):1906-7. PubMed ID: 17993633
    [No Abstract]   [Full Text] [Related]  

  • 5. Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.
    Ravaud A; Sire M
    Ann Oncol; 2009 May; 20(5):966-7; author reply 967. PubMed ID: 19403939
    [No Abstract]   [Full Text] [Related]  

  • 6. [Managing the side effects of angiogenetic inhibitors in metastatic renal cell carcinoma].
    Staehler M; Haseke N; Schöppler G; Stadler T; Heinemann G; Stief CG
    Urologe A; 2006 Oct; 45(10):1333-42; quiz 1343. PubMed ID: 17021905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Role of VEGFR-TKIs in the treatment of renal cell carcinoma].
    Kondo T
    Nihon Jinzo Gakkai Shi; 2012; 54(5):574-80. PubMed ID: 22991835
    [No Abstract]   [Full Text] [Related]  

  • 8. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.
    Tamaskar I; Garcia JA; Elson P; Wood L; Mekhail T; Dreicer R; Rini BI; Bukowski RM
    J Urol; 2008 Jan; 179(1):81-6; discussion 86. PubMed ID: 17997441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New drugs; sunitinib and sorafenib].
    van Bronswijk H; Dubois EA; Osanto S; Cohen AF
    Ned Tijdschr Geneeskd; 2007 Dec; 151(52):2888-90. PubMed ID: 18257434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].
    Bolenz C; Trojan L; Honeck P; Schöppler G; Herrmann E; Alken P; Michel MS; Häcker A
    Aktuelle Urol; 2009 Jan; 40(1):31-6. PubMed ID: 19177319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Management of side effects associated with antiangiogenic treatment in renal cell carcinoma].
    Fléchon A; Boyle H; Négrier S
    Bull Cancer; 2010; 97():73-82. PubMed ID: 20418206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of sunitinib and sorafenib in non-clear cell renal cell carcinoma: results from expanded access studies.
    Strumberg D
    J Clin Oncol; 2008 Jul; 26(20):3469-71; author reply 2471. PubMed ID: 18612169
    [No Abstract]   [Full Text] [Related]  

  • 14. [Anti-angiogenic treatment in the management of metastatic renal cell carcinoma].
    Sire M; Wallerand H; Kilkoski F; Grenier N; Ferrière JM; Ravaud A
    Bull Cancer; 2008 Sep; 95(9):813-20. PubMed ID: 18829413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib and sunitinib.
    Kim A; Balis FM; Widemann BC
    Oncologist; 2009 Aug; 14(8):800-5. PubMed ID: 19648603
    [No Abstract]   [Full Text] [Related]  

  • 16. Two new drugs for renal cell carcinoma.
    Med Lett Drugs Ther; 2007 Feb; 49(1255):18-20. PubMed ID: 17325624
    [No Abstract]   [Full Text] [Related]  

  • 17. Hypothyroidism in patients with renal cell carcinoma: blessing or curse?
    Schmidinger M; Vogl UM; Bojic M; Lamm W; Heinzl H; Haitel A; Clodi M; Kramer G; Zielinski CC
    Cancer; 2011 Feb; 117(3):534-44. PubMed ID: 20845482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.
    Grandinetti CA; Goldspiel BR
    Pharmacotherapy; 2007 Aug; 27(8):1125-44. PubMed ID: 17655513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma.
    Ahn HK; Lee S; Sun JM; Lee J; Park SH; Park JO; Park YS; Kang WK; Lim HY
    Invest New Drugs; 2012 Aug; 30(4):1768-72. PubMed ID: 21720741
    [No Abstract]   [Full Text] [Related]  

  • 20. Progress in the management of advanced renal cell carcinoma (RCC).
    Tong TQ; Rohde D; Peter S
    Aktuelle Urol; 2010 Jan; 41 Suppl 1():S57-60. PubMed ID: 20094957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.